DDInter154 DDInter243
Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes.
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.[L43942,L43947] It continues to be used for the indications mentioned above.
Azelastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bromocriptine
Azelastine {u} (Compound) downregulates {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Bromocriptine
Azelastine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Bromocriptine
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Azelastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Bromocriptine
Azelastine {u} (Compound) downregulates {v} (Gene) CDC45
CDC45 {u} (Gene) regulates {v} (Gene) PHGDH
PHGDH {u} (Gene) is upregulated by {v} (Compound) Bromocriptine
Azelastine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Methysergide
Methysergide {u} (Compound) resembles {v} (Compound) Bromocriptine
Azelastine {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Cyclizine
Cyclizine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Azelastine {u} (Compound) causes {v} (Side Effect) Dysgeusia
Dysgeusia {u} (Side Effect) is caused by {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bromocriptine
Azelastine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) binds {v} (Gene) DRD2
DRD2 {u} (Gene) is bound by {v} (Compound) Bromocriptine
Azelastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound)
Azelastine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Bromocriptine (Compound)
Azelastine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound)
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Azelastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Bromocriptine (Compound)
Azelastine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) regulates PHGDH (Gene) and PHGDH (Gene) is upregulated by Bromocriptine (Compound)
Azelastine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Methysergide (Compound) and Methysergide (Compound) resembles Bromocriptine (Compound)
Azelastine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Cyclizine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Azelastine (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Tamoxifen (Compound) and Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Bromocriptine
Azelastine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) binds DRD2 (Gene) and DRD2 (Gene) is bound by Bromocriptine (Compound)